Title: Interactive Scatter Plot Lattice with Vital Signs Data
Languages: javascript
Libraries: scatterPlotMatrix
Description: A paneled series of scatter plots plotting every measure against every other measure
Tags: interactive, scatter plot, lattice, matrix, bivariate
Data: ../../data/iris.csv, ../../data/safetyData/VS.csv, ../0016-safety-outlier-explorer-hys-law/hy.csv
Code: index.js
Results: example.html
| USUBJID | SITEID | AGE | SEX | RACE | ARM | RFSTDTC | SAFFL | CAT | TEST | STNRLO | STNRHI | STRESU | VISITN | VISIT | DY | STRESN | DT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 38.00 | 5/21/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 58 | 39.00 | 7/17/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 107 | 38.00 | 9/4/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 162 | 34.00 | 10/29/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 218 | 35.00 | 12/24/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 284 | 32.00 | 2/28/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 336 | 35.00 | 4/20/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 355 | 37.00 | 5/9/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 0.65 | 5/21/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 58 | 0.70 | 7/17/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 107 | 1.00 | 9/4/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 162 | 1.25 | 10/29/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 218 | 1.55 | 12/24/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 284 | 1.30 | 2/28/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 336 | 0.95 | 4/20/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 355 | 0.75 | 5/9/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.35 | 5/21/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 58 | 0.30 | 7/17/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 1.20 | 9/4/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 162 | 4.80 | 10/29/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 218 | 6.00 | 12/24/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 284 | 3.50 | 2/28/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 336 | 1.60 | 4/20/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 355 | 0.80 | 5/9/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.30 | 5/21/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 58 | 0.25 | 7/17/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 1.00 | 9/4/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 162 | 4.50 | 10/29/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 218 | 5.75 | 12/24/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 284 | 3.00 | 2/28/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 336 | 1.20 | 4/20/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 355 | 0.60 | 5/9/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 9.00 | 5/21/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 58 | 9.00 | 7/17/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 107 | 12.00 | 9/4/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 162 | 19.00 | 10/29/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 218 | 30.00 | 12/24/15 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 284 | 25.00 | 2/28/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 336 | 18.00 | 4/20/16 | |
| 01-001 | 1 | 30 | F | Other/Mixed | Placebo | 5/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 355 | 12.00 | 5/9/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 25.26 | 5/30/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 52 | 41.36 | 7/20/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 113 | 38.40 | 9/19/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 162 | 41.22 | 11/7/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 228 | 40.53 | 1/12/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 283 | 64.40 | 3/7/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 343 | 33.81 | 5/6/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 372 | 34.89 | 6/4/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 1.40 | 5/30/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 52 | 0.00 | 7/20/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 113 | 0.54 | 9/19/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 162 | 0.91 | 11/7/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 228 | 0.94 | 1/12/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 283 | 0.70 | 3/7/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 343 | 0.64 | 5/6/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 372 | 0.83 | 6/4/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.00 | 5/30/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 52 | 0.58 | 7/20/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 113 | 0.44 | 9/19/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 162 | 0.81 | 11/7/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 228 | 0.35 | 1/12/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 283 | 0.92 | 3/7/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 343 | 0.57 | 5/6/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 372 | 0.91 | 6/4/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.00 | 5/30/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 52 | 0.86 | 7/20/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 113 | 0.30 | 9/19/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 162 | 0.12 | 11/7/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 228 | 0.14 | 1/12/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 283 | 0.00 | 3/7/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 343 | 0.11 | 5/6/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 372 | 0.50 | 6/4/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 22.44 | 5/30/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 52 | 0.00 | 7/20/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 113 | 17.97 | 9/19/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 162 | 15.21 | 11/7/15 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 228 | 18.38 | 1/12/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 283 | 24.37 | 3/7/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 343 | 11.63 | 5/6/16 | |
| 01-002 | 1 | 24 | F | Black | Treatment A | 5/30/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 372 | 23.49 | 6/4/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 36.77 | 8/13/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 55 | 50.39 | 10/6/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 106 | 35.19 | 11/26/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 173 | 58.32 | 2/1/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 220 | 39.07 | 3/19/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 285 | 41.87 | 5/23/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 337 | 48.43 | 7/14/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 365 | 48.09 | 8/11/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 0.90 | 8/13/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 55 | 2.07 | 10/6/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 106 | 1.39 | 11/26/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 173 | 1.15 | 2/1/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 220 | 0.80 | 3/19/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 285 | 1.51 | 5/23/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 337 | 1.42 | 7/14/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 365 | 0.85 | 8/11/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.41 | 8/13/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 55 | 0.44 | 10/6/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 106 | 0.06 | 11/26/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 173 | 0.16 | 2/1/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 220 | 0.65 | 3/19/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 285 | 0.47 | 5/23/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 337 | 0.38 | 7/14/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 365 | 0.00 | 8/11/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.33 | 8/13/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 55 | 0.25 | 10/6/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 106 | 0.47 | 11/26/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 173 | 0.31 | 2/1/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 220 | 0.28 | 3/19/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 285 | 0.00 | 5/23/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 337 | 0.16 | 7/14/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 365 | 0.00 | 8/11/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 5.52 | 8/13/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 55 | 7.60 | 10/6/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 106 | 6.30 | 11/26/15 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 173 | 12.11 | 2/1/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 220 | 11.80 | 3/19/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 285 | 14.28 | 5/23/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 337 | 20.83 | 7/14/16 | |
| 01-003 | 1 | 43 | F | Hispanic | Placebo | 8/13/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 365 | 6.42 | 8/11/16 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 42.74 | 1/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 60 | 46.64 | 3/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 117 | 28.46 | 5/8/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 161 | 29.91 | 6/21/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 224 | 43.71 | 8/23/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 281 | 38.18 | 10/19/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 329 | 37.85 | 12/6/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 367 | 48.37 | 1/13/16 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 0.64 | 1/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 60 | 0.74 | 3/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 117 | 0.53 | 5/8/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 161 | 0.53 | 6/21/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 224 | 0.87 | 8/23/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 281 | 1.06 | 10/19/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 329 | 1.91 | 12/6/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 367 | 0.63 | 1/13/16 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.60 | 1/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 60 | 0.63 | 3/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 117 | 0.31 | 5/8/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 161 | 0.54 | 6/21/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 224 | 0.18 | 8/23/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 281 | 0.40 | 10/19/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 329 | 0.42 | 12/6/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 367 | 0.00 | 1/13/16 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.43 | 1/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 60 | 0.30 | 3/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 117 | 0.77 | 5/8/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 161 | 0.00 | 6/21/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 224 | 0.47 | 8/23/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 281 | 0.00 | 10/19/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 329 | 0.11 | 12/6/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 367 | 0.43 | 1/13/16 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 18.38 | 1/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 60 | 9.85 | 3/12/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 117 | 6.87 | 5/8/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 161 | 14.70 | 6/21/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 224 | 24.41 | 8/23/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 281 | 19.40 | 10/19/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 329 | 20.07 | 12/6/15 | |
| 01-004 | 1 | 42 | F | Hispanic | Placebo | 1/12/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 367 | 20.82 | 1/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 49.81 | 11/11/15 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 61 | 31.14 | 1/10/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 119 | 51.96 | 3/8/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 171 | 50.31 | 4/29/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 225 | 54.23 | 6/22/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 277 | 38.10 | 8/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 338 | 39.39 | 10/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 363 | 43.36 | 11/7/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 1.41 | 11/11/15 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 61 | 0.23 | 1/10/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 119 | 1.37 | 3/8/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 171 | 1.22 | 4/29/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 225 | 0.84 | 6/22/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 277 | 0.77 | 8/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 338 | 1.18 | 10/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 363 | 1.32 | 11/7/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 1.26 | 11/11/15 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 61 | 0.00 | 1/10/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 119 | 0.00 | 3/8/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 171 | 0.51 | 4/29/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 225 | 0.33 | 6/22/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 277 | 0.50 | 8/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 338 | 0.34 | 10/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 363 | 0.75 | 11/7/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.31 | 11/11/15 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 61 | 0.00 | 1/10/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 119 | 0.70 | 3/8/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 171 | 0.00 | 4/29/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 225 | 0.00 | 6/22/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 277 | 0.31 | 8/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 338 | 0.75 | 10/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 363 | 0.25 | 11/7/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 3.15 | 11/11/15 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 61 | 2.29 | 1/10/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 119 | 12.61 | 3/8/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 171 | 13.81 | 4/29/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 225 | 17.50 | 6/22/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 277 | 7.89 | 8/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 338 | 20.49 | 10/13/16 | |
| 01-005 | 1 | 51 | M | White | Treatment B | 11/11/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 363 | 16.05 | 11/7/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 51.10 | 11/21/15 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 58 | 35.03 | 1/17/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 107 | 52.96 | 3/6/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 174 | 61.20 | 5/12/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 222 | 31.53 | 6/29/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 274 | 45.90 | 8/20/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 329 | 27.28 | 10/14/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 356 | 47.90 | 11/10/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 1.05 | 11/21/15 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 58 | 0.47 | 1/17/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 107 | 0.52 | 3/6/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 174 | 0.98 | 5/12/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 222 | 2.55 | 6/29/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 274 | 0.97 | 8/20/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 329 | 2.00 | 10/14/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 356 | 0.75 | 11/10/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.18 | 11/21/15 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 58 | 0.34 | 1/17/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 0.32 | 3/6/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 174 | 0.00 | 5/12/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 222 | 0.09 | 6/29/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 274 | 0.00 | 8/20/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 329 | 0.00 | 10/14/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 356 | 0.23 | 11/10/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.00 | 11/21/15 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 58 | 0.57 | 1/17/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 0.54 | 3/6/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 174 | 0.00 | 5/12/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 222 | 0.00 | 6/29/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 274 | 0.12 | 8/20/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 329 | 0.00 | 10/14/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 356 | 0.21 | 11/10/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 14.02 | 11/21/15 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 58 | 14.10 | 1/17/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 107 | 14.18 | 3/6/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 174 | 18.60 | 5/12/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 222 | 7.73 | 6/29/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 274 | 1.54 | 8/20/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 329 | 4.53 | 10/14/16 | |
| 01-008 | 1 | 53 | F | Black | Treatment B | 11/21/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 356 | 22.92 | 11/10/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 15.34 | 11/25/15 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 57 | 40.64 | 1/20/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 116 | 57.93 | 3/19/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 166 | 37.61 | 5/8/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 218 | 49.27 | 6/29/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 286 | 35.15 | 9/5/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 339 | 58.47 | 10/28/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 358 | 47.24 | 11/16/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 0.92 | 11/25/15 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 57 | 0.68 | 1/20/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 116 | 0.46 | 3/19/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 166 | 1.18 | 5/8/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 218 | 1.07 | 6/29/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 286 | 0.44 | 9/5/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 339 | 2.02 | 10/28/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 358 | 1.63 | 11/16/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.34 | 11/25/15 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 57 | 0.00 | 1/20/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 116 | 1.11 | 3/19/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 166 | 0.00 | 5/8/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 218 | 0.43 | 6/29/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 286 | 0.21 | 9/5/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 339 | 0.46 | 10/28/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 358 | 0.33 | 11/16/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.35 | 11/25/15 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 57 | 0.67 | 1/20/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 116 | 0.58 | 3/19/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 166 | 0.41 | 5/8/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 218 | 0.00 | 6/29/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 286 | 0.38 | 9/5/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 339 | 0.00 | 10/28/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 358 | 0.00 | 11/16/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 22.42 | 11/25/15 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 57 | 14.17 | 1/20/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 116 | 19.16 | 3/19/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 166 | 0.00 | 5/8/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 218 | 13.83 | 6/29/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 286 | 9.96 | 9/5/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 339 | 9.28 | 10/28/16 | |
| 01-009 | 1 | 44 | M | White | Treatment B | 11/25/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 358 | 14.94 | 11/16/16 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 0 | Screening | 1 | 40.18 | 1/6/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 1 | Visit 1 | 56 | 36.41 | 3/2/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 2 | Visit 2 | 107 | 36.61 | 4/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 3 | Visit 3 | 168 | 30.45 | 6/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 4 | Visit 4 | 224 | 36.69 | 8/17/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 5 | Visit 5 | 279 | 52.82 | 10/11/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 6 | Visit 6 | 341 | 56.51 | 12/12/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Albumin | 35 | 55 | g/L | 7 | End of Study | 367 | 33.14 | 1/7/16 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 0 | Screening | 1 | 0.17 | 1/6/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 1 | Visit 1 | 56 | 1.13 | 3/2/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 2 | Visit 2 | 107 | 2.30 | 4/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 3 | Visit 3 | 168 | 0.79 | 6/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 4 | Visit 4 | 224 | 1.60 | 8/17/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 5 | Visit 5 | 279 | 0.64 | 10/11/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 6 | Visit 6 | 341 | 0.85 | 12/12/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Alkaline phosphatase (ALP) | 0.5 | 1.5 | ukat/L | 7 | End of Study | 367 | 0.67 | 1/7/16 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.33 | 1/6/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 56 | 0.00 | 3/2/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 0.57 | 4/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 168 | 0.61 | 6/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 224 | 0.39 | 8/17/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 279 | 0.72 | 10/11/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 341 | 0.23 | 12/12/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, alanine (ALT) | 0 | 0.58 | pkat/L | 7 | End of Study | 367 | 0.34 | 1/7/16 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 0 | Screening | 1 | 0.49 | 1/6/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 1 | Visit 1 | 56 | 0.42 | 3/2/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 2 | Visit 2 | 107 | 0.24 | 4/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 3 | Visit 3 | 168 | 0.19 | 6/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 4 | Visit 4 | 224 | 0.00 | 8/17/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 5 | Visit 5 | 279 | 0.11 | 10/11/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 6 | Visit 6 | 341 | 0.30 | 12/12/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Aminotransferase, aspartate (AST) | 0 | 0.58 | pkat/L | 7 | End of Study | 367 | 0.55 | 1/7/16 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 0 | Screening | 1 | 10.79 | 1/6/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 1 | Visit 1 | 56 | 20.88 | 3/2/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 2 | Visit 2 | 107 | 10.57 | 4/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 3 | Visit 3 | 168 | 22.56 | 6/22/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 4 | Visit 4 | 224 | 14.02 | 8/17/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 5 | Visit 5 | 279 | 6.07 | 10/11/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 6 | Visit 6 | 341 | 13.05 | 12/12/15 | |
| 01-010 | 1 | 35 | F | Black | Treatment B | 1/6/15 | Y | Serum | Total Bilirubin | 5.1 | 20.5 | umol/L | 7 | End of Study | 367 | 8.83 | 1/7/16 |
| <!DOCTYPE html> | |
| <html> | |
| <head> | |
| <title>Interactive Scatter Plot Matrix</title> | |
| <meta http-equiv = 'Content-Type' content = 'text/html; charset = utf-8'> | |
| <script type = 'text/javascript' src = 'https://d3js.org/d3.v3.min.js'></script> | |
| <script type = 'text/javascript' src = 'scatterPlotMatrix.js'></script> | |
| <style> | |
| /*everything*/ | |
| @import url(https://fonts.googleapis.com/css?family = Open+Sans:400,300); | |
| * { | |
| padding: 0; | |
| margin: 0; | |
| font-family: 'Open Sans', Helvetica, Arial, sans-serif; | |
| } | |
| #title { | |
| width: 96%; | |
| margin: 2%; | |
| border-bottom: 1px solid lightgray; | |
| font-weight: lighter; | |
| font-size: 250%; | |
| } | |
| /*tabs*/ | |
| div.tab { | |
| width: 96%; | |
| margin: 2%; | |
| font-weight: lighter; | |
| font-size: 150%; | |
| overflow: hidden; | |
| border: 1px solid #ccc; | |
| background-color: #f1f1f1; | |
| } | |
| div.tab button { | |
| background-color: inherit; | |
| float: left; | |
| border: none; | |
| outline: none; | |
| cursor: pointer; | |
| padding: 14px 16px; | |
| transition: 0.3s; | |
| } | |
| div.tab button:hover { | |
| background-color: #ddd; | |
| } | |
| div.tab button.active { | |
| background-color: #ccc; | |
| } | |
| .tabcontent { | |
| display: none; | |
| padding: 6px 12px; | |
| border: 1px solid #ccc; | |
| border-top: none; | |
| } | |
| /*scatter plots*/ | |
| svg { | |
| font: 10px sans-serif; | |
| padding: 10px; | |
| } | |
| .axis, | |
| .frame { | |
| shape-rendering: crispEdges; | |
| } | |
| .axis line { | |
| stroke: #ddd; | |
| } | |
| .axis path { | |
| display: none; | |
| } | |
| .cell text { | |
| font-weight: bold; | |
| text-transform: capitalize; | |
| } | |
| .frame { | |
| fill: none; | |
| stroke: #aaa; | |
| } | |
| circle { | |
| fill-opacity: .7; | |
| } | |
| circle.hidden { | |
| fill: #ccc !important; | |
| } | |
| .extent { | |
| fill: #000; | |
| fill-opacity: .125; | |
| stroke: #fff; | |
| } | |
| </style> | |
| </head> | |
| <body> | |
| <div class="tab"> | |
| <button class="tablinks active" onclick="openTab(event, 'iris')">Iris Measurements</button> | |
| <button class="tablinks" onclick="openTab(event, 'VS')">Vital Signs</button> | |
| <button class="tablinks" onclick="openTab(event, 'hy')">Liver Function Tests</button> | |
| </div> | |
| <div id="iris" class="tabcontent" style = "display:block"></div> | |
| <div id="VS" class="tabcontent"></div> | |
| <div id="hy" class="tabcontent"></div> | |
| </body> | |
| <script defer type = 'text/javascript' src = 'index.js'></script> | |
| </html> |
| function toggleDetails(){ | |
| var details = document.getElementById("vl-ex-details"); | |
| if (details.style.display === "none") { | |
| details.style.display = "block"; | |
| } else { | |
| details.style.display = "none"; | |
| } | |
| } | |
| function openTab(evt, id) { | |
| // Declare all variables | |
| var i, tabcontent, tablinks; | |
| // Get all elements with class="tabcontent" and hide them | |
| tabcontent = document.getElementsByClassName("tabcontent"); | |
| for (i = 0; i < tabcontent.length; i++) { | |
| tabcontent[i].style.display = "none"; | |
| } | |
| // Get all elements with class="tablinks" and remove the class "active" | |
| tablinks = document.getElementsByClassName("tablinks"); | |
| for (i = 0; i < tablinks.length; i++) { | |
| tablinks[i].className = tablinks[i].className.replace(" active", ""); | |
| } | |
| // Show the current tab, and add an "active" class to the button that opened the tab | |
| document.getElementById(id).style.display = "block"; | |
| evt.currentTarget.className += " active"; | |
| } | |
| function toggleDetails(){ | |
| var details = document.getElementById("vl-ex-details"); | |
| if (details.style.display === "none") { | |
| details.style.display = "block"; | |
| } else { | |
| details.style.display = "none"; | |
| } | |
| } | |
| /*------------------------------------------------------------------------------------------------\ | |
| Iris Measurements | |
| \------------------------------------------------------------------------------------------------*/ | |
| var element3 = '#iris'; | |
| var dataPath3 = 'https://rhoinc.github.io/data-library/data/miscellaneous/iris.csv'; | |
| var settings3 = { | |
| keys: ['observation'], | |
| measure_col: 'dimension', | |
| measures: ['sepal length', 'sepal width', 'petal length', 'petal width'], | |
| result_col: 'length', | |
| group_col: 'species', | |
| size: 200, | |
| padding: 20}; | |
| d3.csv(dataPath3, function(data) { | |
| var transposed = []; | |
| data.forEach((d,i) => { | |
| settings3.measures.forEach(measure => { | |
| transposed.push( | |
| {observation: i | |
| ,dimension: measure | |
| ,length: d[measure] | |
| ,species: d.species}); | |
| }); | |
| }); | |
| scatterPlotMatrix | |
| (element3 | |
| ,transposed | |
| ,settings3); | |
| }); | |
| /*------------------------------------------------------------------------------------------------\ | |
| Vital Signs | |
| \------------------------------------------------------------------------------------------------*/ | |
| var element1 = '#VS'; | |
| var dataPath1 = 'https://rhoinc.github.io/data-library/data/clinical-trials/sdtm/vs.csv'; | |
| var settings1 = { | |
| keys: ['USUBJID', 'VISIT'], | |
| measure_col: 'VSTEST', | |
| result_col: 'VSSTRESN', | |
| group_col: 'site', | |
| size: 200, | |
| padding: 20}; | |
| d3.csv(dataPath1, function(data) { | |
| data.forEach(function(d) { | |
| d.VSSTRESN = +d.VSSTRESN; | |
| d.site = d.USUBJID.split('-')[0]; | |
| d.VSSTNRLO = +d.VSSTNRLO; | |
| d.VSSTNRHI = +d.VSSTNRHI; | |
| d.level = d.VSSTRESN >= d.VSSTNRLO && d.VSSTRESN <= d.VSSTNRHI | |
| ? 'Normal' | |
| : d.VSSTRESN < d.VSSTNRLO | |
| ? 'Low' | |
| : 'High'; | |
| }); | |
| scatterPlotMatrix | |
| (element1 | |
| ,data.filter(d => d.VISIT === 'Screening') | |
| ,settings1); | |
| }); | |
| /*------------------------------------------------------------------------------------------------\ | |
| Liver Function Tests | |
| \------------------------------------------------------------------------------------------------*/ | |
| var element2 = '#hy'; | |
| var dataPath2 = './hy.csv'; | |
| var settings2 = { | |
| keys: ['USUBJID', 'VISIT'], | |
| measure_col: 'TEST', | |
| result_col: 'STRESN', | |
| group_col: 'VISIT', | |
| size: 200, | |
| padding: 20}; | |
| d3.csv(dataPath2, function(data) { | |
| data.forEach(function(d) { | |
| d.site = d.USUBJID.split('-')[0]; | |
| }); | |
| scatterPlotMatrix | |
| (element2 | |
| ,data | |
| ,settings2); | |
| }); |
| { | |
| "homepage":"example.html", | |
| "main": "index.js", | |
| "name": "scatter-plot-matrix", | |
| "label":"Interactive Scatter Plot Lattice with Vital Signs Data", | |
| "version": "1.0.1", | |
| "description": "A paneled series of scatter plots plotting every measure against every other measure", | |
| "author": "Rho, Inc.", | |
| "license": "MIT", | |
| "keywords":["javascript","interactive", "scatter plot", "lattice", "matrix", "bivariate"], | |
| "dependencies": { | |
| "d3": "~3" | |
| }, | |
| "dataDependecies":[ | |
| "../../data/iris.csv", | |
| "../../data/safetyData/SDTM/VS.csv", | |
| "../0016-safety-outlier-explorer-hys-law/hy.csv" | |
| ] | |
| } |
| /*------------------------------------------------------------------------------------------------\ | |
| Functions | |
| \------------------------------------------------------------------------------------------------*/ | |
| //generate data array representing matrix of one item per measure combination | |
| function cross(a, b) { | |
| var c = [], | |
| n = a.length, | |
| m = b.length, | |
| i, | |
| j; | |
| for (i = -1; ++i < n;) | |
| for (j = -1; ++j < m;) | |
| c.push( | |
| {x: a[i] | |
| ,i: i | |
| ,y: b[j] | |
| ,j: j}); | |
| return c; | |
| } | |
| function scatterPlotMatrix(element, data, settings) { | |
| //main object | |
| var scatterPlotMatrix = {}; | |
| scatterPlotMatrix.element = element; | |
| scatterPlotMatrix.selection = d3.select(element); | |
| //settings | |
| if (!settings.measures) | |
| settings.measures = d3.set( | |
| data.map(d => d[settings.measure_col])) | |
| .values(); | |
| settings.nMeasures = settings.measures.length; | |
| scatterPlotMatrix.settings = Object.assign({}, settings); | |
| //data | |
| scatterPlotMatrix.data = {raw: data}; | |
| scatterPlotMatrix.data.raw | |
| .forEach(d => { | |
| d[settings.result_col] = +d[settings.result_col]; | |
| }); | |
| scatterPlotMatrix.data.measures = settings.measures | |
| .map(measure => { | |
| var summary = {}; | |
| summary.measure = measure; | |
| summary.data = data.filter(d => d[settings.measure_col] === measure); | |
| summary.values = summary.data.map(d => +d[settings.result_col]).sort(); | |
| summary.domain = d3.extent(summary.values); | |
| return summary; | |
| }); | |
| scatterPlotMatrix.data.crossed = cross(scatterPlotMatrix.data.measures,scatterPlotMatrix.data.measures); | |
| //x | |
| scatterPlotMatrix.xScale = d3.scale.linear() | |
| .range([settings.padding / 2, settings.size - settings.padding / 2]); | |
| scatterPlotMatrix.xAxis = d3.svg.axis() | |
| .scale(scatterPlotMatrix.xScale) | |
| .orient('bottom') | |
| .ticks(6); | |
| scatterPlotMatrix.xAxis.tickSize(settings.size * settings.nMeasures); | |
| //y | |
| scatterPlotMatrix.yScale = d3.scale.linear() | |
| .range([settings.size - settings.padding / 2, settings.padding / 2]); | |
| scatterPlotMatrix.yAxis = d3.svg.axis() | |
| .scale(scatterPlotMatrix.yScale) | |
| .orient('left') | |
| .ticks(6); | |
| scatterPlotMatrix.yAxis.tickSize(-settings.size * settings.nMeasures); | |
| //color | |
| scatterPlotMatrix.colorScale = d3.scale.category10(); | |
| var svg = scatterPlotMatrix.selection | |
| .append('svg') | |
| .attr('width', settings.size * settings.nMeasures + settings.padding) | |
| .attr('height', settings.size * settings.nMeasures + settings.padding) | |
| .append('g') | |
| .attr('transform', 'translate(' + settings.padding + ',' + settings.padding / 2 + ')'); | |
| svg.selectAll('g.x.axis') | |
| .data(scatterPlotMatrix.data.measures) | |
| .enter() | |
| .append('g') | |
| .classed('x axis', true) | |
| .attr('transform', function(d, i) { | |
| return 'translate(' + (settings.nMeasures - i - 1) * settings.size + ',0)'; }) | |
| .each(function(d) { | |
| scatterPlotMatrix.xScale | |
| .domain(d.domain); | |
| d3.select(this) | |
| .call(scatterPlotMatrix.xAxis); | |
| }); | |
| svg.selectAll('g.y.axis') | |
| .data(scatterPlotMatrix.data.measures) | |
| .enter() | |
| .append('g') | |
| .classed('y axis', true) | |
| .attr('transform', function(d, i) { | |
| return 'translate(0,' + i * settings.size + ')'; }) | |
| .each(function(d) { | |
| scatterPlotMatrix.yScale | |
| .domain(d.domain); | |
| d3.select(this) | |
| .call(scatterPlotMatrix.yAxis); | |
| }); | |
| function plot(p) { | |
| var cell = d3.select(this); | |
| scatterPlotMatrix.xScale.domain(p.x.domain); | |
| scatterPlotMatrix.yScale.domain(p.y.domain); | |
| var rect = cell.append('rect') | |
| .attr('class', 'frame') | |
| .attr('x', settings.padding / 2) | |
| .attr('y', settings.padding / 2) | |
| .attr('width', settings.size - settings.padding) | |
| .attr('height', settings.size - settings.padding); | |
| var bivariateData = data | |
| .filter(d => | |
| d[settings.measure_col] === p.x.measure || | |
| d[settings.measure_col] === p.y.measure); | |
| var nested = d3.nest() | |
| .key(d => settings.keys.map(key => d[key]).concat(d[settings.group_col]).join('||')) | |
| .rollup(d => { | |
| var results = {}; | |
| d.forEach(di => { | |
| var measure = di[settings.measure_col]; | |
| results[measure] = di[settings.result_col]; | |
| }); | |
| return results; | |
| }) | |
| .entries(bivariateData); | |
| var transposed = []; | |
| nested.forEach((d,i) => { | |
| settings.keys | |
| .forEach((key,j) => { | |
| d.values[key] = d.key.split('||')[j]; | |
| }); | |
| d.values[settings.group_col] = d.key.split('||')[settings.keys.length]; | |
| transposed.push(d.values); | |
| }); | |
| var points = cell.selectAll('circle') | |
| .data(transposed) | |
| .enter() | |
| .append('circle') | |
| .attr('cx', function(d) { return scatterPlotMatrix.xScale(d[p.x.measure]); }) | |
| .attr('cy', function(d) { return scatterPlotMatrix.yScale(d[p.y.measure]); }) | |
| .attr('r', 4) | |
| .style('fill', function(d) { return scatterPlotMatrix.colorScale(d[settings.group_col]); }); | |
| } | |
| var cells = svg.selectAll('g.cell') | |
| .data(scatterPlotMatrix.data.crossed) | |
| .enter() | |
| .append('g') | |
| .classed('cell', true) | |
| .attr('transform', function(d) { | |
| var x = (settings.nMeasures - d.i - 1) * settings.size; | |
| var y = d.j * settings.size; | |
| return 'translate(' + x + ',' + y + ')'; }) | |
| .each(plot); | |
| //Titles for the diagonal. | |
| cells.filter(function(d) { return d.i === d.j; }) | |
| .append('text') | |
| .attr('x', settings.padding) | |
| .attr('y', settings.padding) | |
| .attr('dy', '.71em') | |
| .text(function(d) { | |
| return d.x.measure; }); | |
| //Brushing. | |
| var brush = d3.svg.brush() | |
| .x(scatterPlotMatrix.xScale) | |
| .y(scatterPlotMatrix.yScale) | |
| .on('brushstart', brushstart) | |
| .on('brush', brushmove) | |
| .on('brushend', brushend); | |
| var brushCell; | |
| //Clear the previously-active brush, if any. | |
| function brushstart(p) { | |
| if (brushCell !== this) { | |
| d3.select(brushCell).call(brush.clear()); | |
| scatterPlotMatrix.xScale.domain(p.x.domain); | |
| scatterPlotMatrix.yScale.domain(p.y.domain); | |
| brushCell = this; | |
| } | |
| } | |
| //Highlight the selected circles. | |
| function brushmove(p) { | |
| var e = brush.extent(); | |
| svg.selectAll('circle') | |
| .classed('hidden', function(d) { | |
| return e[0][0] > d[p.x.measure] || d[p.x.measure] > e[1][0] | |
| || e[0][1] > d[p.y.measure] || d[p.y.measure] > e[1][1]; | |
| }); | |
| } | |
| //If the brush is empty, select all circles. | |
| function brushend() { | |
| if (brush.empty()) | |
| svg.selectAll('.hidden') | |
| .classed('hidden', false); | |
| } | |
| cells.call(brush); | |
| return scatterPlotMatrix; | |
| } |